Clopidogrel Pharmacogenetics, resistance to antiplatelet therapy in ischemic stroke by Epigenome Wide Association Study (EWAS).


Autoria(s): Gallego Fàbrega, Cristina
Contribuinte(s)

Universitat de Vic. Escola Politècnica Superior

Universitat de Vic. Màster Universitari en Anàlisi de Dades Òmiques

Data(s)

01/03/2014

Resumo

Clopidogrel is a widely used antiplatelet drug used in preventing vascular events after suffering a first stoke. Genome-wide association studies (GWAS) has not been able to establish a clear association between polymorphisms and recurrence. Therefore in the present final master project an epigenetic approach is proposed. Using an array based technology, 450.000 CpG sites across all genome were assessed in 48 individuals (21 cases and 21 controls). Looking at differentially methylated levels between cases and controls, 58 CpG sites (DMGs) were found. Although, no clear locus was observed. Looking individually to each 49 genes, two appeared to be important to our study. TRAF3 and ADAMTS2 are gens highly related to platelet aggregation. In orther to confirm these result, a new DNA methylation study will be done in a larger cohort, using Sequenom technology.

Formato

25 p.

Identificador

http://hdl.handle.net/10854/2816

Idioma(s)

eng

Direitos

Aquest document està subjecte a una llicència Creative Commons:

Palavras-Chave #Epigenètica #ADN #Malalties cerebrovasculars
Tipo

info:eu-repo/semantics/masterThesis